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The development of precision medicine 
in clinical practice
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Abstract 
Precision medicine allows a dramatic expansion of biological data, while there is still an urgent need to understand 
and insight the exact meaning of those data to human health and disease. This has led to an increasing wealth of 
data unanalyzed. The concept of precision medicine is about the customization of healthcare, with decisions and 
practices tailored to an individual patient based on their intrinsic biology in addition to clinical “signs and symptoms”. 
Construction of a standardized model for the integration of data from various platforms is the central mission of 
the ‘New Disease Management Model’. The model is helpful for the development of new taxonomy of diseases and 
subtypes, to personalize therapy based on patient genetic profiles. A rapid progression of precision therapy has been 
made recently. Clinical trials have shown the therapeutic efficacy of discovered and developed therapeutic agents has 
improved. However, next-generation drugs would be designed for disease subtypes with more specificity, efficacy 
and lower toxicity.
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An enormous amount of biological data are generated 
and continues to expand dramatically, with the comple-
tion of Human Genome Project and the introduction of 
the next-generation sequencing. The efficiency of com-
piling, organizing and analyzing the data to extract a 
true understanding of fundamental biological processes 
of human health and disease has not kept pace, leading 
to an increasing wealth of unanalyzed data [1]. In 2011, 
national research council of the national academies have 
published “Toward precision medicine: Building a knowl-
edge network for biomedical research and a new tax-
onomy of disease”, which suggests that genomic findings 
promote the integration of information between biomed-
ical research and clinical medicine [1].
Precision medicine aims to harness large amounts of 
data available from the human genome and the subse-
quent research wave of the molecular basis of disease. 
This allows the customization of healthcare and inte-
gration of electronic medical information on both an 
individual and larger global scale. With decisions and 
practices being tailored to the individual patient based 
their intrinsic biology in addition to traditional physical 
signs and symptoms [2]. There is a distinct from other 
similar ideas of personalized medicine, in that precision 
medicine implies that unique treatments can be designed 
for each individual, severe taxonomic needs of the bio-
medical research and medical communities, providing a 
profound definition of diseases subtypes at the molecular 
level. Ultimately, precision medicine allows for more pre-
cise diagnosis and treatment at the intrinsic molecular 
level.
With advances of information technology, such as elec-
tronic medical records, it is possible to acquire detailed 
clinical data about individual patients and computational 
tools for analyzing large sets of data provide a means to 
search for unexpected correlations with enormous data. 
Recent development of large-scale and multilevel omics-
based biotechnologies, e.g. proteomics, metabolomics, 
genomics, phenomics, diverse cellular assays, provides 
precision medicine with powerful methodological bases 
and creates great potentials for improving healthcare [3]. 
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Precision oncology is referred to as the vanguard of preci-
sion medicine. Cancer is a genomic disease with a series 
of mutated or altered oncogenes, while oncology research 
has benefited from the large scale biotechnology studies 
of cancer genomes. The translation of analyzed data has 
also revealed scores of cancer genes affecting cell signal-
ing, chromatin, epigenomic regulation, metabolism, and 
lineage maturation [4]. Recently, the Obama adminis-
tration announced a research initiative geared towards 
precision medicine and to the new era of medicine both 
delivering the right treatment at the right time [5].
Translational medicine research is the main compo-
nent of precision medicine’s integration of large sets of 
bioinformatics data with medical practice. Numerous 
translational research centers are emerging constantly 
and launch translational projects. In 2012, the Interna-
tional Personal Genome Project published an integrated 
map of genetic variation from 1092 human genomes, 
which revealed substantial genetic variation among 
populations. These variations will be helpful to under-
stand genetic variations among different ethnic and 
racial backgrounds as well as how these variants affect 
drug metabolism [6, 7]. In 2013, British Prime Minister 
David Cameron, launched the ‘100,000 people genome 
project’, with results published and available to the public 
at no cost [8]. This genetic and phenotypic information 
revealed through this projection will enable researchers 
to use the data to identify genes linked to medical con-
ditions, develop new treatments and facilitate improve-
ments in precision medicine.
In addition, other large-scale projects, such as The 
Cancer Genome Atlas (TCGA), Encyclopedia of DNA 
Elements (ENCODE), or Human Proteome Project 
(HPP), were launched [9, 10]. TCGA contains somatic 
mutations, copy number variation, mRNA expression, 
miRNA expression, protein expression, and histol-
ogy slides, and aims to develop an integrated landscape 
of complex molecular network for approximately 7000 
human tumors. The ENCODE project has mapped 
regions of transcription, transcription factor association, 
histone modification, DNA methylation and chromatin 
structure to delineate all functional elements encoded 
in the human genome [11]. HPP aims to reach a detailed 
understanding of the ~20,000 human protein-coding 
gene predicted from the human genome. Recently, the 
Chromosome-centric Human Proteome Project [10, 12] 
and tissue-based maps of human proteomes [13] have 
been described. The project has extensively and sys-
tematically analyzed all missing and known proteins in 
chromosomes for their tissue/cellular/subcellular locali-
zations as well as their associations with human diseases 
(i.e., immune diseases, metabolic disorders, and cancers). 
Tissue-based maps of human proteomes have identified 
differences in druggable proteins, cancer proteins, and 
their metabolism between different tissues and organs.
A secretome as complete sets of secreted proteins is 
an important part of the proteome. Secretomes encode 
approximately 10  % of the human genome and play 
important roles in cellular immunity, adhesion, com-
munication, and various drug delivery mechanisms 
[14]. Analyses of secretomes have been reported in vari-
ous organisms and cell types [15]. The Secreted Protein 
Database is a collection of over 18,000 secreted proteins 
from Human, Mouse and Rat proteomes, which includes 
sequences from SwissProt, Trembl, Ensembl and Refseq 
[16]. Studying cell secretomes can be helpful in identify-
ing biomarkers needed for diagnosis, prognosis and/or 
monitoring therapeutic response [14].
There still remains the need to build a linked library 
network as well as new taxonomy profiles of diseases 
for the better implementation of precision medicine, 
although enormous data have been generated and shown 
contribution to precision diagnosis, pharmaceutical 
development. The network should be integrated for the 
convenience of searching information including indi-
vidual genome, transcriptome, proteome, metabolome, 
phenome, data from clinical signs and symptoms, experi-
mental tests, environmental exposures, and socioeco-
nomic factors. This provides a deeper understanding of 
disease mechanisms, pathogenesis, treatment, and drive 
forward the development of new taxonomy to define dis-
ease subtypes. However, data from different platforms 
are not standardized. Building a standardized model for 
the integration of data is a major challenge.
Bioinformatics data provide great insights to the 
understanding of the biological processes of human dis-
eases and health. Computational data mining methods 
are important tools for the prioritization of disease can-
didate gene. The gene network-based guilt-by-association 
is the basic principle from which genes with the same 
interaction partners or expression data, most likely share 
the same biological function [17]. There are various data 
sources and network measures for disease gene prior-
itization [18]. For example, Gene Ontology and KEGG 
enable the functional interpretation of genes and gene 
products via enrichment analysis. NCBI LocusLink, 
Ensemble, SwissPro, or TrEmbl provide protein sequence 
data, probably associated with diseases. Network analysis 
can be done using either local network information such 
as direct neighbor, shortest path or degree of a node. 
Global network information can be taken into account 
the entire network topology to rank candidate genes [18]. 
The limitation should not go unnoticed and under-devel-
oped, although data mining tools have greatly benefited 
researchers to identify candidate genes. For instance, not 
all functional data has been annotated in Gene Ontology 
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and KEGG, resulting in inevitable omissions of potential 
key molecular pathways. Most of the mining methods 
rely on previous reported data information available for 
diseases. This limits the prediction potential for genes 
related to diseases.
The development of target-specific drugs has made 
great progression in improving therapeutic response of 
various diseases, on basis of a deeper biological under-
standing of diseases and an efficient validation of clinical 
therapeutic effects. For example, the epidermal growth 
factor receptor (EGFR) pathway has been targeted for 
the treatment of patients with somatic EGFR mutant 
non-small-cell lung carcinoma (NSCLC). EGFR tyrosine 
kinase inhibitors (TKIs) such as erlotinib and gefitinib 
have confirmed significant improvements in the ‘progres-
sion-free survival’, in advanced EGFR mutated NSCLC 
[19, 20]. Other target-specific drugs include HER2 tar-
geted agents (e.g. lapatinib, pertuzumab), ABL inhibitors 
(e.g. imatinib, nilotinib), MEK inhibitor (e.g. trametinib), 
or immune checkpoint inhibitors (e.g. anti-CTLA4 
monoclonal antibody agents, ipilimumab). Most of the 
therapeutic targets are critical molecular signaling path-
ways associated with development of disease. Targeting 
specific molecular or effectors of different diseases have 
shown therapeutic advantages and great potential as an 
important aspect of precision medicine.
However, a large number of challenges should be con-
sidered and overcome during the development and clini-
cal application of targeted agents. Various toxicities and 
developments of new targeted molecular therapies were 
revealed [21], including cardiac, pulmonary, skin, endo-
crine, gastrointestinal toxicities caused by new targeted 
therapies. It is urgent to develop more specific, efficacious 
targeted therapies with low toxicities. Additionally, drug 
resistance has been inevitably observed in some patients 
who were expected to have a better response before use. 
The resistance mechanisms should be further investi-
gated for potential solutions or the development of anti-
resistant next-generation targeted agents. For example, 
the development of acquired EGFR inhibitor resistance 
have been studied to be involved in a number of mecha-
nisms, such as the T790M missense mutation in exon 
20 of the EGFR kinase domain and escape mechanisms 
through critical genetic drivers, including c-MET/HGF, 
HER2, PIK3CA, ERK, BRAF, CRKL, and AXL [22]. The 
next-generation EGFR inhibitors, such as afatinib, can 
bind to both EGFR and HER2 through covalent bonds 
resulting in the irreversible blockade, and be developed 
with more sustained target modulation [23]. The third-
generation EGFR inhibitors to focus on T790M-mediated 
drug resistance are currently in clinical trial testing [23].
In conclusion, precision medicine has shown great 
potentialities while catering to the requirements of 
bioinformatics and medical practice development. Build-
ing a standardized model for the integration of data from 
various platforms is the central mission which is helpful 
for the development of new taxonomy of disease sub-
types and personalized therapy based on patient genetic 
profiles. Furthermore, there has been progress towards 
the discovery and development of targeted therapeutic 
agents with evidence in clinical trials of the improvement 
of therapeutic efficacy. Next-generation drugs would be 
designed for diseases subtypes with more specificity, effi-
cacy and lower toxicity.
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